How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s ...
Most of us are guilty of romanticizing the past. Do you long to be the captain of a tall ship? Just as long as you don’t mind weevils in your food, vitamin deficiencies, and death from an ...
CFO Sarah Friar confirmed at Goldman Sachs' Communacopia conference that OpenAI's frontier models helped architect the very ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results